The research was co-led by Professor Matthew McKay of the University of Melbourne, and Research Assistant Professor Ahmed Abdul Quadeer of the Department of Electronic and Computer Engineering of the HKUST.
In May 2022, the new monkeypox virus was first observed. Over 52,000 cases have been confirmed in more than 90 countries and regions globally.
The research team conducted genomic analysis within weeks of the emergence of the new monkeypox virus strain in order to understand whether the genetic mutation observed in this year’s monkeypox outbreak would affect the immune response to the monkeypox virus produced by the vaccine.
Matthew said that the high effectiveness of the smallpox vaccine against the monkeypox virus had been confirmed in past outbreaks of monkeypox virus, and it is regarded as an important measure in preventing large outbreaks.
However, because the monkeypox virus that caused this year’s outbreak was new, scientific data to prove the vaccine’s protective effect is lacking.
The research team found that the immune response targeted the antigenic epitopes of the vaccinia virus and the new monkeypox virus because of their genetic similarities.
The findings may reduce anxiety about the new monkeypox virus.
“Based on the analysis of the study, we expect that the immune response generated by the smallpox vaccine will still be effective against the new monkeypox virus, same as the monkeypox virus that appeared in the past. Our data further support the use of smallpox vaccines recommended by different health authorities worldwide against the new monkeypox virus,” Ahmed said.
But he also said that while genetic sequencing and immunology data have provided evidence to expect a strong immune response, clinical studies are still needed to determine the exact efficacy of these vaccines against the new monkeypox virus.